There exists many types and subtypes of breast cancer, meaning every patient is different and thus requires an individualised treatment approach.
Some patients will see their disease return in the long-term, which is why there is a critical need to continue to optimise early breast cancer care and to do more to prevent the disease evolving to an advanced, incurable stage. By combining pharmaceutical science, strong diagnostic, digital and genomic capabilities, we are able to innovate and develop treatment options tailored to each individual’s needs. Our advanced diagnostic solutions, and most notably the use of biomarker testing, bring us closer to fulfilling our long-term ambition of offering patients personalised treatment approaches. It’s been an immense challenge, but ongoing research efforts are finally bearing fruit for this challenging disease.
We believe there is room for improving outcomes for people with breast cancer. Our focus lies in identifying new targets, refining and exploring immunotherapy approaches, and investigating new treatment combinations.
The advances in AI technology have revolutionised diagnostics, providing healthcare professionals with more precise answers and allowing them to provide their patients with a wider array of treatment options. Existing and new treatment options offer hope for those living with breast cancer.
© 2023, Roche Products (New Zealand) Ltd, Auckland. This site is intended for New Zealand audiences. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site.
M-NZ-00000625-v6.0/MR9618/NOV23. This site was last updated NOV2023